mRNA research highlights South Carolina’s growing role in life sciences innovation

South Carolina’s life sciences sector is growing rapidly, and new advances in mRNA-based cancer research are drawing attention to the state’s expanding role in medical innovation.

mRNA technology is now being studied for a broader range of uses, including personalized cancer treatment. Researchers are exploring how mRNA-based therapies can help train the immune system to recognize and attack cancer cells based on the unique characteristics of an individual patient’s tumor.

The developments come as South Carolina continues to build momentum in life sciences, a sector that includes biotechnology, pharmaceuticals, medical devices, health IT, research laboratories and advanced manufacturing. According to SCbio, the industry includes more than 1,000 firms statewide, supports more than 87,000 jobs and generates an estimated $25.7 billion in annual economic impact.

The Upstate has become an important part of that growth.

Greenville has emerged as a market for medical technology, biotechnology and pharmaceutical companies. Anderson-based Poly-Med develops bioresorbable polymers used in medical devices and drug delivery. Clemson University, Prisma Health, Furman University and the University of South Carolina collaborate through the Health Sciences Center on the Greenville Memorial Medical Campus. Clemson’s Biomedical Engineering Innovation Campus is located on Prisma Health’s Patewood campus, and Greenwood Genetic Center has long been recognized for its work in medical genetics.

Downtown Greenville is also home to Main Street Labs, a life sciences laboratory hub that provides space for growing companies. One of its tenants, Kiyatec, is a clinical-stage cancer diagnostics company with roots in technology developed at Clemson University.

Together, those assets have helped position the Upstate as a growing life sciences center within South Carolina’s broader innovation economy.

Recent developments in mRNA cancer research show why that ecosystem could become increasingly important. In cancer care, some mRNA-based treatments are being studied not as traditional preventive vaccines, but as personalized therapies used after diagnosis. The goal is to help the body identify and target remaining cancer cells after surgery or other treatment.

Melanoma is one area where researchers have reported promising results. More than 112,000 Americans are expected to be diagnosed with invasive melanoma this year, and more than 8,500 are expected to die from the disease. Treatment for advanced melanoma has changed significantly over the past decade, particularly with the growth of immunotherapy.

Recent clinical trial results involving a personalized mRNA-based cancer treatment combined with immunotherapy showed a significant reduction in the risk of melanoma recurrence or death. The treatment remains under study, but researchers say it points toward a future in which cancer care may become more precise and individualized.

South Carolina is already connected to that research. MUSC Hollings Cancer Center has highlighted clinical trials using mRNA technology to develop personalized cancer treatments intended to help prevent cancer from returning. While that work is based in Charleston, life sciences leaders say medical breakthroughs can have statewide effects, influencing research funding, patient care, workforce development and business recruitment.

The Upstate’s existing strengths could make the region well positioned for future growth in the sector. Life sciences companies often require technical talent, precision manufacturing, quality control systems, supplier networks, clinical partnerships and research infrastructure — areas where the Upstate has already developed a strong foundation through advanced manufacturing, higher education and health care.

The region also benefits from a growing network of academic and medical institutions. Prisma Health’s Upstate market includes major medical campuses, research and education facilities, community hospitals and specialty services. Clemson, Furman, USC School of Medicine Greenville, VCOM Carolinas and the technical college system all contribute to the region’s health care and life sciences workforce.

As South Carolina’s population grows and ages, access to new medical technologies is expected to become increasingly important. Cancer, heart disease, Alzheimer’s disease and other serious conditions will place continued demand on health systems, researchers and companies developing new treatments.

For economic development officials, the growth of mRNA research is part of a larger trend: life sciences is becoming a more competitive industry for states seeking high-wage jobs, private investment and research activity. South Carolina’s ability to attract and retain companies in the sector may depend on continued investment in workforce training, lab space, university partnerships and policies that support responsible innovation.

The promise of mRNA technology remains under study, and not every treatment being tested will reach patients. But the research reflects a broader shift in medicine toward therapies that are more personalized, data-driven and connected to advanced manufacturing and biotechnology.

For the Upstate, that shift could create new opportunities in research, clinical care, diagnostics, medical devices and life sciences manufacturing.

South Carolina’s life sciences sector has already become a significant part of the state’s economy. As mRNA research and other medical technologies continue to advance, the Upstate may play a growing role in shaping what comes next.